The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.
Jason Edward Faris
No relevant relationships to disclose
Lawrence Scott Blaszkowsky
No relevant relationships to disclose
Eunice Lee Kwak
No relevant relationships to disclose
David Tsai Ting
No relevant relationships to disclose
Andrew X. Zhu
Consultant or Advisory Role - Daiichi Sankyo; Eisai; Exelixis; Sanofi
Research Funding - Bayer Schering Pharma; Lilly
Jeffrey W. Clark
No relevant relationships to disclose
Jill N. Allen
No relevant relationships to disclose
Hui Zheng
No relevant relationships to disclose
Dan G. Duda
No relevant relationships to disclose
Theodore S. Hong
No relevant relationships to disclose
Jennifer Yon-Li Wo
No relevant relationships to disclose
Janet E. Murphy
No relevant relationships to disclose
Lipika Goyal
No relevant relationships to disclose
Jeffrey A. Meyerhardt
No relevant relationships to disclose
Nadine Jackson McCleary
No relevant relationships to disclose
Kimmie Ng
No relevant relationships to disclose
Jennifer A. Chan
No relevant relationships to disclose
Charles S. Fuchs
No relevant relationships to disclose
David P. Ryan
No relevant relationships to disclose
Matthew Kulke
No relevant relationships to disclose